Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-&agr;-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
US6387880B1 · kind B1 · utility
0Cited by
9References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 1996 |
| Grant date | May 14, 2002 |
| Priority date | — |
| Expiry date | Apr 22, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/198
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is for pharmaceutical compositions and a method of use for the transdermal delivery of N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L-&agr;-aspartyl]-L-phenylalanine or its esters and their pharmaceutically acceptable salts which are useful as platelet aggregation inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.